Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-06
2010-12-14
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S304000
Reexamination Certificate
active
07851467
ABSTRACT:
The invention provides novel benzoimidazolone-carboxamide-derived carbamate 5-HT4receptor agonist compounds of formula (I):wherein R1, R2, R3, R4, a, and b are defined in the disclosure. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4receptor activity, and processes and intermediates useful for preparing such compounds.
REFERENCES:
patent: 5223511 (1993-06-01), Turconi et al.
patent: 5753673 (1998-05-01), Ohuchi et al.
patent: 6002009 (1999-12-01), Cereda et al.
patent: 6117882 (2000-09-01), Schaus et al.
patent: 6281218 (2001-08-01), Cereda et al.
patent: 7317022 (2008-01-01), Gendron et al.
patent: 7351704 (2008-04-01), Marquess et al.
patent: 7375114 (2008-05-01), Marquess et al.
patent: 7396933 (2008-07-01), Choi et al.
patent: 7399862 (2008-07-01), Choi et al.
patent: 7419989 (2008-09-01), Fatheree et al.
patent: 2002/0173505 (2002-11-01), Skogvall
patent: 2005/0148573 (2005-07-01), Katsu et al.
patent: 2006/0199839 (2006-09-01), Goldblum et al.
patent: 2008/0070923 (2008-03-01), Gendron et al.
patent: 0 309 423 (1989-03-01), None
patent: 01298271 (1999-12-01), None
Thomas A. Godwin (Gastrointestinal Diseases, http://edcenter.med.cornell.edu/CUMC—PathNotes/Gastrointestinal/Gastrointestinal.html, Aug. 2004, 51 pages.
Baxter et al., “Benzimidazolone derivatives act as 5-HT4receptor ligands in rat oesophagus”, European Journal of Pharmacology, 212, pp. 225-229 (1992).
Dumuis et al., “Characterization of a novel 5-HT4receptor antagonist of the azabicycloalkyl benzimidazolone class: DAU 6285”, Naunyn-Schmiedeberg's Arch Pharmacol, 345, pp. 264-269 (1992).
Dumuis et al., “Azabicycloalkyl benzimidazolone derivatives as a novel class of potent agonists at the 5-HT4receptor positively coupled to adenylate cyclase in brain”, Naunyn-Schmiedeberg's Arch Pharmacol, 343, pp. 245-251 (1991).
Schaus et al., “Synthesis and structure—activity relationships of potent and orally active 5-HT4 receptor antagonists: indazole and benzimidazolone derivatives”, Journal of Medicinal Chemistry, 41(11) pp. 1943-1955 (1998).
Tapia et al., “2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with Selective Affinity for the 5-HT4Receptor: Synthesis and Structure-Affinity and Structure-Activity Relationships of a New Series of Partial Agonist and Antagonist Derivatives”, J. Med. Chem., 42, pp. 2870-2880 (1999).
Turconi et al., “Azabicycloalkyl benzimidazolones: Interaction with serotonergic 5-HT3and 5-HT4receptors and potential therapeutic implications”, Drugs of the Future, 16(11), pp. 1011-1026 (1991).
Turconi et al., “Synthesis of a New Class of 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carobxylic Acid Derivatives as Highly Potent 5-HT3Receptor Antagonists”, J. Med. Chem., 33, pp. 2101-2108 (1990).
Bouras et al., “Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacutation disorder”, Gastroenterology, 120, pp. 354-360 (2001).
Briejer et al., “Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”, Neurogastroenterol. Mot., 13, pp. 465-472 (2001).
Briejer et al., “The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”, European Journal of Pharmacology, 423, pp. 71-83 (2001).
De Winter et al., “Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats”, Gut, 45, pp. 713-718 (1999).
Grider et al., “5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine”, Gastroenterology, 115, pp. 370-380 (1998).
Gullikson et al., “SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamine4 receptor mechanism”, The Journal of Pharmacology and Experimental Therapeutics, 264(1), pp. 240-248 (1992).
Langlois et al., “5-HT4 receptor ligands: applications and new prospects”, Journal of Medicinal Chemistry, 46(3), pp. 319-344 (2003).
Muller-Lissner et al., “Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation”, Aliment Pharmacol Ther, 21, pp. 11-20 (2005).
Zelnorm, Physicians Desk Reference, PDR Electronic Library (TM), http://www.thomsonhc.com/pdrel/librarian/ND—PR/Pdr/PFPUI/a31qVUv1Lt1cXv/DDAK/ . . . Mar. 6, 2007.
Choi Seok-Ki
Fatheree Paul R.
Goldblum Adam A.
Long Daniel D.
Marquess Daniel
Hagenah Jeffrey A.
Saxon Roberta P.
Stockton Laura L.
Theravance Inc.
LandOfFree
Carbamate compounds as 5-HT 4 receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamate compounds as 5-HT 4 receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamate compounds as 5-HT 4 receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4174919